Research on Telehealth Ketamine Outcomes

The evidence base for telehealth ketamine specifically—distinct from IV ketamine in clinical settings—is still developing. This guide summarizes the current state of research, its limitations, and what conclusions can reasonably be drawn.

Why Specific Telehealth Ketamine Research Is Needed

The robust evidence base for IV ketamine in treatment-resistant depression does not automatically transfer to telehealth sublingual or oral ketamine. The two modalities differ in:

• Bioavailability: IV 100% vs. sublingual 25-35%
• Peak plasma concentration: IV produces much higher peaks
• Experience quality: IV typically produces more intense dissociation and altered states
• Setting: Clinical supervision vs. home environment
• Patient population: Clinic-based trials often enroll more severe, complex cases

Studies demonstrating IV ketamine efficacy are evidence that the mechanism works. They are not direct evidence that lower-bioavailability sublingual ketamine in a home setting produces equivalent outcomes. For a detailed comparison of these delivery methods, see telehealth vs. in-person clinics.

Industry-Sponsored Outcomes Data

The largest datasets on telehealth ketamine outcomes come from the platforms themselves.

Major Platform Outcomes Study (2022 Publication)

One of the largest direct-to-consumer telehealth ketamine platforms published a retrospective outcomes analysis in the Journal of Affective Disorders examining over 1,200 patients who completed their program.

Key findings:

• 89% of patients with depression experienced clinically significant improvement in depressive symptoms (PHQ-9 reduction ≥5 points)
• 62% achieved remission (PHQ-9 < 5)
• 89% of patients with anxiety showed clinically significant improvement (GAD-7 reduction)
• Mean PHQ-9 decreased from 18.9 (moderately severe) to 8.9 (mild)

Limitations:

• Industry-sponsored, not independently peer-reviewed at the time
• No comparison group (no control, no comparator treatment)
• High dropout rate in real-world data (patients who stopped treatment early are often excluded from "completer" analyses, which may inflate reported outcomes)
• Self-reported outcomes in some components

Despite these limitations, the dataset is large enough to be informative and suggests meaningful clinical benefit in a real-world population.

Daily Low-Dose Platform Data

Some daily low-dose platforms have released limited outcomes data suggesting significant depression improvement in a majority of their patients, but this data has not been published in peer-reviewed form as of early 2025.

Academic Research on Sublingual/Oral Ketamine

Several academic studies have examined oral or sublingual ketamine formulations for depression and other conditions:

Lim et al. (Australia, 2021)

This pilot study of subcutaneous (not strictly sublingual, but similarly bioavailable) at-home ketamine for treatment-resistant depression demonstrated significant depressive symptom reduction in a small cohort with no serious adverse events. This study provides important proof-of-concept for home-based ketamine delivery.

Grunebaum et al. (2017)

A Columbia University study examined sublingual ketamine vs. IV ketamine in depressed patients with suicidal ideation. Both routes showed anti-suicidal effects, with sublingual showing a delayed but meaningful response. This study was in a closely monitored research setting, not an at-home model.

European Subcutaneous Ketamine Studies

Several European research groups have published on subcutaneous ketamine for palliative and psychiatric applications in home settings with nurse monitoring. These studies collectively suggest that home-based ketamine can be administered safely with appropriate oversight. Our at-home safety data article compiles the available safety evidence from major platforms.

Comparison Data: Telehealth vs. In-Person

Direct head-to-head comparison studies between telehealth at-home and in-person IV ketamine are limited. The available comparison data is largely inferential:

Efficacy comparison: IV ketamine at 0.5 mg/kg produces response rates of 50-70% in TRD in controlled trials. The 89% improvement rate reported by one major telehealth platform appears higher, but this likely reflects: (1) a lower severity threshold for enrollment than clinical trials, (2) "improvement" defined more broadly than "response" in clinical trials, and (3) completers-only analysis.

Safety comparison: Published adverse event rates for IV ketamine in clinical settings are well-characterized and generally very low for serious events. Telehealth adverse event data, while also suggesting low serious event rates, is less systematically collected.

What the Research Justifies (and What It Does Not)

Justified conclusions:

• Sublingual ketamine at therapeutic doses produces meaningful antidepressant effects in real-world populations
• Adverse event rates for at-home sublingual ketamine in screened populations appear low
• The at-home model is feasible and acceptable to patients (high completion rates in industry data)

Not yet justified:

• That at-home sublingual ketamine is equivalent in efficacy to IV ketamine for severe TRD
• That the long-term safety profile of at-home sublingual ketamine is as well-characterized as IV
• That the outcomes achieved in industry-sponsored datasets reflect what can be expected at less rigorous platforms

The Research Agenda

The telehealth ketamine research agenda that would strengthen the evidence base:

• Independent (non-industry-sponsored) randomized controlled trials of at-home sublingual ketamine vs. comparators
• Head-to-head comparisons of sublingual and IV routes
• Long-term follow-up data (12-24 months)
• Research in populations not well-represented in current datasets (severe cases, older patients, minorities)
• Systematic adverse event reporting and analysis

Academic centers including Columbia, Yale, UCSF, and Stanford are conducting or planning research in this space. The next 3-5 years should see substantially better evidence.

The Evidence Standard for Current Decision-Making

For patients deciding whether to pursue telehealth ketamine, the available evidence supports a reasonable conclusion: at-home sublingual ketamine, delivered by a reputable provider to appropriately screened patients, is likely to produce meaningful benefit for depression and anxiety with a manageable safety profile. This is not the level of evidence from a well-powered RCT—but it is genuine, real-world clinical data from a large patient population.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service